GlassScriptPhysician profile
Ria Viray
NPI 1750017737
$1,221.33
in general payments reported to CMS, 2019-2025
18 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.70 · 2023: $535 · 2024: $269 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $315.12 | 2024-2025 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $216.91 | 2023 | |
| Abiomed | $186.62 | 2024-2025 | Impella |
| Novo Nordisk INC | $98.81 | 2023 | Rybelsus, Ozempic |
| Medtronic, INC. | $81.77 | 2023 | Corevalve Evolut R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.01 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $39.43 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $30.51 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $30.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.68 | 2023 | Fasenra, Farxiga |
| Getinge USA Sales, LLC | $25.32 | 2025 | Vasoview Hemopro 2 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.33 | 2025 | Lifevest |
| Phadia US INC. | $21.73 | 2023 | Immunocap |
| Zimmer Biomet Holdings, INC. | $19.64 | 2025 | Venapax |
| Pfizer INC. | $17.00 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $16.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.24 | 2022 | |
| Phathom Pharmaceuticals, INC. | $10.11 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ria Viray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.